When delegates returned from the 38th annual JP Morgan Healthcare Conference in San Diego in mid-January this year, few can have imagined just how fast, and how dramatically, the biotech industry was about to change. Fewer than 10,000 cases of COVID-19 had been reported to the WHO by the end of that month, and few, other than infectious disease specialists, were taking very much notice of those reports. Dave Mead, director of a biotech company based near Cambridge, Isogenica,  and a delegate at the JP Morgan event, remembers the abruptness of the change. “By early February we in…